Capricor's Deramiocel Gets November 2026 FDA Review Date

Capricor Therapeutics' deramiocel BLA now carries a November 22, 2026, PDUFA action date, a three-month extension triggered by the FDA's acceptance of additional HOPE-3 data as a major amendment, a classification that signals the agency views the submission as substantively changed and requiring a full review cycle reset. For regulatory affairs leads tracking cell therapy BLAs, the sequence of events here, a complete response letter, a negative advisory committee vote, and a post-adcom data package, represents one of the more instructive recent case studies in biologics review complexity.

The FDA's Center for Biologics Evaluation and Research accepted the amendment, which includes 24-month open-label extension findings and additional robustness analyses from the phase 3 HOPE-3 trial (NCT05126758). Capricor submitted the package following a July 29, 2026, advisory committee meeting at which panelists voted 9 to 3 against recommending approval. Committee members questioned post-randomization revisions to the statistical analysis plan and expressed skepticism that left ventricular ejection fraction constitutes a validated surrogate endpoint for clinical benefit in this population; a signal of increased left ventricular volume also drew scrutiny. The agency cited substantial unmet need in DMD when acknowledging the amendment.

The regulatory path to this point has been protracted. The original BLA was accepted in March 2025 under a PDUFA date of August 31, 2025, before the FDA issued a complete response letter in July 2025 citing insufficient evidence of effectiveness and unresolved chemistry, manufacturing, and controls (CMC) elements. Capricor resubmitted with the completed HOPE-3 dataset; the agency designated it a class 2 review with an August 22, 2026, action date, the date now superseded by the major amendment extension. QA and CMC teams reviewing this sequence should note that unresolved manufacturing controls contributed to the initial CRL even as clinical data continued to accumulate.

HOPE-3 enrolled 106 boys and young men with DMD, the majority nonambulatory, randomized to intravenous deramiocel at 150 million cells or placebo every three months for 12 months. The trial met its primary endpoint, a 54% slowing of decline on the Performance of Upper Limb v2.0 (P =.029, ITT population, n = 105), and its key secondary endpoint, a 91% slowing of LVEF decline by centrally read cardiac MRI (P =.041, n = 83). Hypersensitivity reactions were the most frequently reported adverse events, managed with glucocorticoid and H1/H2-blocker pretreatment; no unexpected safety signals emerged in extended HOPE-2 follow-up.

The refined proposed indication Capricor submitted centers on preservation of upper limb function, aligning the label request directly with the trial's primary endpoint and potentially narrowing the evidentiary burden the agency must weigh against the adcom's nonbinding recommendation.

The FDA's final decision on deramiocel, now due by November 22, 2026, will test whether a post-adcom data package and a narrowed indication can overcome a negative panel vote in the absence of an approved alternative for this population.

Source: CGTlive via cgtlive.com, August 24, 2026.